Form 8-K - Current report:
SEC Accession No. 0001140361-25-009063
Filing Date
2025-03-17
Accepted
2025-03-17 16:32:13
Documents
14
Period of Report
2025-03-17
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ef20045625_8k.htm   iXBRL 8-K 32704
2 EXHIBIT 99.1 ef20045625_ex99-1.htm EX-99.1 5250
  Complete submission text file 0001140361-25-009063.txt   177159

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA bbio-20250317.xsd EX-101.SCH 3985
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE bbio-20250317_lab.xml EX-101.LAB 21966
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE bbio-20250317_pre.xml EX-101.PRE 16046
16 EXTRACTED XBRL INSTANCE DOCUMENT ef20045625_8k_htm.xml XML 4225
Mailing Address 3160 PORTER DR. SUITE 250 PALO ALTO CA 94304
Business Address 3160 PORTER DR. SUITE 250 PALO ALTO CA 94304 (650) 391-9740
BridgeBio Pharma, Inc. (Filer) CIK: 0001743881 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38959 | Film No.: 25745011
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)